Immix Biopharma recently reported a positive clinical update for the registrational NEXICART-2 trial, evaluating lead CAR-T candidate NXC-201 in relapsed/refractory amyloid light chain amyloidosis (r/r ALA). We believe that both the safety and efficacy data offer promise to this fragile patient pop
09 Jan 2026
Immix Biopharma:NXC-201's path to BLA submission
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Immix Biopharma:NXC-201's path to BLA submission
Immix Biopharma, Inc. (IMMX:NAS) | 0 0 0.0%
- Published:
09 Jan 2026 -
Author:
Jyoti Prakash, CFA | Arron Aatkar, PhD -
Pages:
6 -
Immix Biopharma recently reported a positive clinical update for the registrational NEXICART-2 trial, evaluating lead CAR-T candidate NXC-201 in relapsed/refractory amyloid light chain amyloidosis (r/r ALA). We believe that both the safety and efficacy data offer promise to this fragile patient pop